BiomX Inc. (PHGE)

NYSEAMERICAN: PHGE · IEX Real-Time Price · USD
0.290
-0.006 (-1.99%)
Apr 19, 2024, 1:54 PM EDT - Market open
-1.99%
Market Cap 16.01M
Revenue (ttm) n/a
Net Income (ttm) -26.17M
Shares Out 55.22M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,452
Open 0.282
Previous Close 0.296
Day's Range 0.281 - 0.298
52-Week Range 0.187 - 0.855
Beta 1.36
Analysts Strong Buy
Price Target 2.00 (+589.89%)
Earnings Date Apr 3, 2024

About PHGE

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 58
Stock Exchange NYSEAMERICAN
Ticker Symbol PHGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PHGE stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target
$2.0
(589.89% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BiomX Announces the Appointment of Susan Blum to its Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

1 day ago - GlobeNewsWire

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies ...

15 days ago - GlobeNewsWire

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline

16 days ago - GlobeNewsWire

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

23 days ago - GlobeNewsWire

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients...

4 weeks ago - GlobeNewsWire

Shareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage Therapeutics

MILWAUKEE , March 7, 2024 /PRNewswire/ -- Ademi LLP is investigating BiomX (NYSE American: PHGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptive Ph...

6 weeks ago - PRNewsWire

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Acquisition will create phage therapy company with an advanced pipeline with two P hase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis ( “ CF ”) patients and BX ...

6 weeks ago - GlobeNewsWire

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies t...

3 months ago - GlobeNewsWire

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...

5 months ago - GlobeNewsWire

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV1 1 and C ystic F ibrosis Questionnaire - R evised (CFQ-R) respiratory domain in a predefined subgroup of patient...

5 months ago - GlobeNewsWire

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month

5 months ago - GlobeNewsWire

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...

6 months ago - GlobeNewsWire

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies t...

6 months ago - GlobeNewsWire

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

8 months ago - GlobeNewsWire

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

8 months ago - GlobeNewsWire

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates

9 months ago - GlobeNewsWire

BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...

9 months ago - GlobeNewsWire

NYSE American Initiates Delisting Proceedings for BiomX Warrants

Shares of the Company's common stock and units (PHGE and PHGE.U) are unaffected by delisting proceedings of warrants and will remain trading on NYSE American Shares of the Company's common stock and u...

11 months ago - GlobeNewsWire

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of BiomX Inc. (PHGE.WS)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Biom...

11 months ago - Business Wire

BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered p...

11 months ago - GlobeNewsWire

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); Results from Part 2 Expected in Third Quarter of 2023

1 year ago - GlobeNewsWire

BiomX Announces the Appointments of Jason M. Marks and Michael E.

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered p...

1 year ago - GlobeNewsWire

BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered p...

1 year ago - GlobeNewsWire

BiomX Announces Second Closing of $7.5 Million Private Placement

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered p...

1 year ago - GlobeNewsWire